Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, discusses the clinical trials that influenced plasminogen's (Ryplazim; Kedrion Biopharma) FDA approval, as well as details valuable information for the treatment of patients with plasminogen deficiency.
Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, continues her discussion on plasminogen deficiency type 1 by highlighting the recent FDA approval of plasminogen (Ryplazim; Kedrion Biopharma), the first treatment specifically indicated for this disorder.
/PRNewswire/ The "Plasma Therapy Global Market Report 2024" has been added to ResearchAndMarkets.com s offering. The plasma therapy market size has grown.
9 drugs now in shortage beckershospitalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from beckershospitalreview.com Daily Mail and Mail on Sunday newspapers.